title: Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
abstract: BACKGROUND
  Few biomarkers of ovarian cancer prognosis have been established, partly because subtype-specific associations might be obscured in studies combining all histopathological subtypes. We examined whether tumour expression of the progesterone receptor (PR) and oestrogen receptor (ER) was associated with subtype-specific survival.
  
  
  METHODS
  12 studies participating in the Ovarian Tumor Tissue Analysis consortium contributed tissue microarray sections and clinical data to our study. Participants included in our analysis had been diagnosed with invasive serous, mucinous, endometrioid, or clear-cell carcinomas of the ovary. For a patient to be eligible, tissue microarrays, clinical follow-up data, age at diagnosis, and tumour grade and stage had to be available. Clinical data were obtained from medical records, cancer registries, death certificates, pathology reports, and review of histological slides. PR and ER statuses were assessed by central immunohistochemistry analysis done by masked pathologists. PR and ER staining was defined as negative (<1% tumour cell nuclei), weak (1 to <50%), or strong (≥50%). Associations with disease-specific survival were assessed.
  
  
  RESULTS
  2933 women with invasive epithelial ovarian cancer were included: 1742 with high-grade serous carcinoma, 110 with low-grade serous carcinoma, 207 with mucinous carcinoma, 484 with endometrioid carcinoma, and 390 with clear-cell carcinoma. PR expression was associated with improved disease-specific survival in endometrioid carcinoma (log-rank p<0·0001) and high-grade serous carcinoma (log-rank p=0·0006), and ER expression was associated with improved disease-specific survival in endometrioid carcinoma (log-rank p<0·0001). We recorded no significant associations for mucinous, clear-cell, or low-grade serous carcinoma. Positive hormone-receptor expression (weak or strong staining for PR or ER, or both) was associated with significantly improved disease-specific survival in endometrioid carcinoma compared with negative hormone-receptor expression, independent of study site, age, stage, and grade (hazard ratio 0·33, 95% CI 0·21-0·51; p<0·0001). Strong PR expression was independently associated with improved disease-specific survival in high-grade serous carcinoma (0·71, 0·55-0·91; p=0·0080), but weak PR expression was not (1·02, 0·89-1·18; p=0·74).
  
  
  CONCLUSIONS
  PR and ER are prognostic biomarkers for endometrioid and high-grade serous ovarian cancers. Clinical trials, stratified by subtype and biomarker status, are needed to establish whether hormone-receptor status predicts response to endocrine treatment, and whether it could guide personalised treatment for ovarian cancer.
  
  
  BACKGROUND
  Carraresi Foundation and others.
authors.affiliation: Division of Epidemiology, Department of Health Research and Policy, Stanford University, Stanford, CA, USA.
authors.forename: Weiva
authors.initials: W
authors.lastname: Sieh
authors.forename: Martin
authors.initials: M
authors.lastname: Köbel
authors.forename: Teri A
authors.initials: TA
authors.lastname: Longacre
authors.forename: David D
authors.initials: DD
authors.lastname: Bowtell
authors.forename: Anna
authors.initials: A
authors.lastname: deFazio
authors.forename: Marc T
authors.initials: MT
authors.lastname: Goodman
authors.forename: Estrid
authors.initials: E
authors.lastname: Høgdall
authors.forename: Suha
authors.initials: S
authors.lastname: Deen
authors.forename: Nicolas
authors.initials: N
authors.lastname: Wentzensen
authors.forename: Kirsten B
authors.initials: KB
authors.lastname: Moysich
authors.forename: James D
authors.initials: JD
authors.lastname: Brenton
authors.forename: Blaise A
authors.initials: BA
authors.lastname: Clarke
authors.forename: Usha
authors.initials: U
authors.lastname: Menon
authors.forename: C Blake
authors.initials: CB
authors.lastname: Gilks
authors.forename: Andre
authors.initials: A
authors.lastname: Kim
authors.forename: Jason
authors.initials: J
authors.lastname: Madore
authors.forename: Sian
authors.initials: S
authors.lastname: Fereday
authors.forename: Joshy
authors.initials: J
authors.lastname: George
authors.forename: Laura
authors.initials: L
authors.lastname: Galletta
authors.forename: Galina
authors.initials: G
authors.lastname: Lurie
authors.forename: Lynne R
authors.initials: LR
authors.lastname: Wilkens
authors.forename: Michael E
authors.initials: ME
authors.lastname: Carney
authors.forename: Pamela J
authors.initials: PJ
authors.lastname: Thompson
authors.forename: Rayna K
authors.initials: RK
authors.lastname: Matsuno
authors.forename: Susanne Krüger
authors.initials: SK
authors.lastname: Kjær
authors.forename: Allan
authors.initials: A
authors.lastname: Jensen
authors.forename: Claus
authors.initials: C
authors.lastname: Høgdall
authors.forename: Kimberly R
authors.initials: KR
authors.lastname: Kalli
authors.forename: Brooke L
authors.initials: BL
authors.lastname: Fridley
authors.forename: Gary L
authors.initials: GL
authors.lastname: Keeney
authors.forename: Robert A
authors.initials: RA
authors.lastname: Vierkant
authors.forename: Julie M
authors.initials: JM
authors.lastname: Cunningham
authors.forename: Louise A
authors.initials: LA
authors.lastname: Brinton
authors.forename: Hannah P
authors.initials: HP
authors.lastname: Yang
authors.forename: Mark E
authors.initials: ME
authors.lastname: Sherman
authors.forename: Montserrat
authors.initials: M
authors.lastname: García-Closas
authors.forename: Jolanta
authors.initials: J
authors.lastname: Lissowska
authors.forename: Kunle
authors.initials: K
authors.lastname: Odunsi
authors.forename: Carl
authors.initials: C
authors.lastname: Morrison
authors.forename: Shashikant
authors.initials: S
authors.lastname: Lele
authors.forename: Wiam
authors.initials: W
authors.lastname: Bshara
authors.forename: Lara
authors.initials: L
authors.lastname: Sucheston
authors.forename: Mercedes
authors.initials: M
authors.lastname: Jimenez-Linan
authors.forename: Kristy
authors.initials: K
authors.lastname: Driver
authors.forename: Jennifer
authors.initials: J
authors.lastname: Alsop
authors.forename: Marie
authors.initials: M
authors.lastname: Mack
authors.forename: Valerie
authors.initials: V
authors.lastname: McGuire
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Rothstein
authors.forename: Barry P
authors.initials: BP
authors.lastname: Rosen
authors.forename: Marcus Q
authors.initials: MQ
authors.lastname: Bernardini
authors.forename: Helen
authors.initials: H
authors.lastname: Mackay
authors.forename: Amit
authors.initials: A
authors.lastname: Oza
authors.forename: Eva L
authors.initials: EL
authors.lastname: Wozniak
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Benjamin
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Gentry-Maharaj
authors.forename: Simon A
authors.initials: SA
authors.lastname: Gayther
authors.forename: Anna V
authors.initials: AV
authors.lastname: Tinker
authors.forename: Leah M
authors.initials: LM
authors.lastname: Prentice
authors.forename: Christine
authors.initials: C
authors.lastname: Chow
authors.forename: Michael S
authors.initials: MS
authors.lastname: Anglesio
authors.forename: Sharon E
authors.initials: SE
authors.lastname: Johnatty
authors.forename: Georgia
authors.initials: G
authors.lastname: Chenevix-Trench
authors.forename: Alice S
authors.initials: AS
authors.lastname: Whittemore
authors.forename: Paul D P
authors.initials: PD
authors.lastname: Pharoah
authors.forename: Ellen L
authors.initials: EL
authors.lastname: Goode
authors.forename: David G
authors.initials: DG
authors.lastname: Huntsman
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Ramus
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D014408:Biomarkers, Tumor / Q000378:metabolism; D018269:Carcinoma, Endometrioid / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D016022:Case-Control Studies; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D010053:Ovary / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D015996:Survival Rate; D046888:Tissue Array Analysis
chemical_list: D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone